INOVIO’s DNA medicines are precisely designed DNA plasmids delivered through INOVIO’s proprietary investigational smart device — CELLECTRA® — directly into the body’s cells to generate an immune response to potentially treat or prevent disease.
JACQUELINE SHEA, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER
“We are entering a new era in DNA medicines and INOVIO is forging the path by bringing a 21st century approach to both the optimization of DNA plasmids and the delivery of these plasmids through our CELLECTRA® smart device.”
ROBERT J. JUBA JR.
Senior Vice President, Biological Manufacturing and Clinical Supply Management
“INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”
Senior Vice President, Engineering Development
“INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses. This delivery has enabled us to overcome a key limitation of other DNA and other nucleic acid approaches, such as mRNA.”
MARK TWYMAN, MBA
Chief Commercial Officer
“The goal of our DNA medicines is to redefine success in the treatment of HPV-related diseases, as well as other infectious diseases, and cancers. We are not just talking about incremental improvements.”
CHIEF FINANCIAL OFFICER
“Our excellent team at INOVIO is driven to realize the potential of DNA medicines to meet urgent health needs associated with HPV-related diseases, cancer, and infectious diseases. We will not rest until we deliver on this potential.”
JEFFREY SKOLNIK, M.D.
SENIOR VICE PRESIDENT, CLINICAL DEVELOPMENT
“Our goal at INOVIO is to drive the development of DNA medicines as a new way to effectively and safely treat or prevent cancers from destroying lives. We are proud to be at the forefront of this potential game-changing approach to defeating cancer.”
© Copyright 2022 INOVIO Pharmaceuticals. All rights reserved.